Madrigal Pharmaceuticals, Inc.
MDGL
Rank in Stocks
#2023
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Share Price
$446.50
Market Cap
$10.32B
Change (1 day)
-0.72%
Change (1 year)
1.73%
Country
US
Trade Madrigal Pharmaceuticals, Inc. (MDGL)
Category
Healthcare
Stock split history for Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc. stock (symbol: MDGL) underwent a total of 1 stock splits.
The most recent stock split occurred on Jul 25, 2016.
One MDGL share bought prior to Jul 25, 2016 would equal to 0.028571428571429 MDGL shares today.
The most recent stock split occurred on Jul 25, 2016.
One MDGL share bought prior to Jul 25, 2016 would equal to 0.028571428571429 MDGL shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| 2016-07-25 | 1:35 | x0.028571428571429 | x0.028571428571429 |
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
